AAPS PharmSci 360: Insights on Challenges and Trends in Softgel Formulations
Emerging Trends in Softgel Formulations
During the AAPS PharmSci 360 conference, Karunakar Sukuru, RPh, PhD, the global vice-president of RX Product Development at Catalent Pharma Solutions, addressed the evolving challenges faced in softgel formulations. The primary concerns include increasing solubility and ensuring the stability of these solubilized molecules, which directly impacts bioavailability.
Addressing Industry Shifts
- Non-Animal Products: The pharmaceutical industry is witnessing a growing demand for non-animal products, especially in Europe.
- Gelatin Shell Challenges: Though gelatin is a robust material for softgels, it poses cross-linking challenges that necessitate innovative solutions.
Missed Opportunities in Drug Delivery
Sukuru emphasized that softgels represent one of the most adaptable dosage forms available today, capable of delivering drugs via various routes. However, he noted that this potential remains largely untapped. Softgels can be administered through oral, ophthalmic, nasal, and other routes, which challenges common misconceptions regarding their cost-effectiveness compared to alternatives like spray drying technology.
Engagement at AAPS PharmSci 360
Attendees of AAPS PharmSci 360 can look forward to Sukuru’s presentation on Oct. 21, focusing on enhanced bioavailability and moderated drug release via softgel formulations. Visit Catalent at Booth #1141 for further insights.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.